化工儀器網(wǎng)
技術(shù)文章
Evaluation of poly(lactic-co-glycolic acid) and poly(dl-lactide-co-ε-caprolactone) electrospun fiber
閱讀：680 發(fā)布時(shí)間：2018-1-30作者： Sla E. Aniagyeia. Lee B. Simsa. Danial A. Malikc. Kevin M. Tyoc,e. Keegan C. Currya. Woihwan Kimb. Daniel A. Hodgea. Jinghua Duana,e. Jill M. Steinbach-Rankinsa,c,d,e.
a
Department of Bioengineering, University of Louisville, Louisville, KY 40202, United States
b
Department of Medicine, University of Louisville, Louisville, KY 40202, United States
c
Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, United States
d
Department of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, United States
e
Center for Predictive Medicine, University of Louisville, Louisville, KY 40202, United States
摘要：More diverse multipurpose prevention technologies are urgently needed to provide localized, topical pre-exposure prophylaxis against sexually transmitted infections (STIs). In this work, we established the foundation for a multipurpose platform, in the form of polymeric electrospun fibers (EFs), to physicochemically treat herpes simplex virus 2 (HSV-2) infection. To initiate this study, we fabricated different formulations of poly(lactic-co-glycolic acid) (PLGA) and poly(dl-lactide-co-ε-caprolactone) (PLCL) EFs that encapsulate Acyclovir (ACV), to treat HSV-2 infection in vitro. Our goals were to assess the release and efficacy differences provided by these two different biodegradable polymers, and to determine how differing concentrations of ACV affected fiber efficacy against HSV-2 infection and the safety of each platform in vitro. Each formulation of PLGA and PLCL EFs exhibited high encapsulation efficiency of ACV, sustained-delivery of ACV through one month, and in vitro biocompatibility at the highest doses of EFs tested. Additionally, all EF formulations provided complete and efficacious protection against HSV-2 infection in vitro, regardless of the timeframe of collected fiber eluates tested. This work demonstrates the potential for PLGA and PLCL EFs as delivery platforms against HSV-2, and indicates that these delivery vehicles may be expanded upon to provide protection against other sexually transmitted infections.